Nykode vaccine shows its worth in cervical cancer trial

Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.